← Leaderboards
Srikumar P Chellappan
Columbia University Health Sciences
$11,182,462
Attributed
$11,182,462
Total exposure
9
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.4M · FY2005–21$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$11,182,462 · 9
By mechanism
R01$8,164,175 · 5
P01$2,035,809 · 2
U54$579,341 · 1
R21$403,137 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Cell Proliferation”
- John M Lachin · George Washington University$118,921,924
- David M Nathan · Massachusetts Institute Of Technology$118,921,924
- David Heimbrook · Leidos Biomedical Research, Inc.$103,164,048
- Timothy J Eberlein · Washington University$49,931,668
- Deirdre R. Meldrum · University Of Washington$37,202,510
- Robert A Weinberg · Whitehead Institute For Biomedical Res$32,735,166
Research focus
Cell ProliferationSignal TransductionMalignant NeoplasmsTumorProteinsEventBaseIn VivoPhosphorylationAngiogenesisNeoplasm MetastasisCellsMolecularReportingMouse ModelResponseMediatingTumor GrowthAffectApoptosisResearch StudyCancer CellIn VitroGrowth
Grant awards (43)
CARM1-mediated regulation of YAP1 as a therapeutic target in lung cancer$437,443
R01 · FY2021 · CA · contact PI
CARM1-mediated regulation of YAP1 as a therapeutic target in lung cancer$437,443
R01 · FY2020 · CA · contact PI
Understanding how mitotic kinases drive EMT in breast cancers$190,408
U54 · FY2019 · CA · contact PI
Understanding how mitotic kinases drive EMT in breast cancers$192,638
U54 · FY2018 · CA · contact PI
Understanding how mitotic kinases drive EMT in breast cancers$196,295
U54 · FY2017 · CA · contact PI
TBK1 mediated regulation of E2F1 as a therapeutic target in non-small cell lung cancer$183,244
R21 · FY2016 · CA · contact PI
TBK1 mediated regulation of E2F1 as a therapeutic target in non-small cell lung cancer$219,893
R21 · FY2015 · CA · contact PI
Role of Id1 in NSCLC Progression and Metastasis$322,898
R01 · FY2013 · CA · contact PI
Role of Id1 in NSCLC Progression and Metastasis$344,596
R01 · FY2012 · CA · contact PI
Role of Beta-arrestin-1 and Src in nAChR Signaling and Lung Caancer$336,129
R01 · FY2012 · CA · contact PI
Role of Beta-arrestin-1 and Src in nAChR Signaling and Lung Caancer$336,129
R01 · FY2011 · CA · contact PI
Rb-Raf1 Disrupters as Anti-Cancer Drugs$310,679
P01 · FY2011 · CA · contact PI
Administration$91,026
P01 · FY2011 · CA · contact PI
Role of Beta-arrestin-1 and Src in nAChR Signaling and Lung Caancer$346,525
R01 · FY2010 · CA · contact PI
Role of Id1 in NSCLC Progression and Metastasis$345,576
R01 · FY2010 · CA · contact PI
Rb-Raf1 Disrupters as Anti-Cancer Drugs$334,543
P01 · FY2010 · CA · contact PI
Administration$98,456
P01 · FY2010 · CA · contact PI
Role of Id1 in NSCLC Progression and Metastasis$346,525
R01 · FY2009 · CA · contact PI
Role of Beta-arrestin-1 and Src in nAChR Signaling and Lung Caancer$346,007
R01 · FY2009 · CA · contact PI
Rb-Raf1 Disrupters as Anti-Cancer Drugs$327,064
P01 · FY2009 · CA · contact PI
PROHIBITIN GENE IN GROWTH CONTROL AND TUMOR SUPPRESSION$273,469
R01 · FY2009 · CA · contact PI
Administration$96,694
P01 · FY2009 · CA · contact PI
Role of Beta-arrestin-1 and Src in nAChR Signaling and Lung Caancer$344,450
R01 · FY2008 · CA · contact PI
Rb-Raf1 Disrupters as Anti-Cancer Drugs$302,911
P01 · FY2008 · CA · contact PI
PROHIBITIN GENE IN GROWTH CONTROL AND TUMOR SUPPRESSION$272,261
R01 · FY2008 · CA · contact PI
Administration$89,974
P01 · FY2008 · CA · contact PI
Rb-Raf1 Disrupters as Anti-Cancer Drugs$293,903
P01 · FY2007 · CA · contact PI
E2F TRANSCRIPTION FACTOR AND TUMOR SUPPRESSION$290,561
R01 · FY2007 · CA · contact PI
PROHIBITIN GENE IN GROWTH CONTROL AND TUMOR SUPPRESSION$267,428
R01 · FY2007 · CA · contact PI
Administration$90,559
P01 · FY2007 · CA · contact PI
E2F TRANSCRIPTION FACTOR AND TUMOR SUPPRESSION$299,239
R01 · FY2006 · CA · contact PI
PROHIBITIN GENE IN GROWTH CONTROL AND TUMOR SUPPRESSION$275,415
R01 · FY2006 · CA · contact PI
E2F TRANSCRIPTION FACTOR AND TUMOR SUPPRESSION$306,440
R01 · FY2005 · CA
PROHIBITIN GENE IN GROWTH CONTROL AND TUMOR SUPPRESSION$282,043
R01 · FY2005 · CA
E2F TRANSCRIPTION FACTOR AND TUMOR SUPPRESSION$306,440
R01 · FY2004 · CA
E2F TRANSCRIPTION FACTOR AND TUMOR SUPPRESSION$302,523
R01 · FY2003 · CA
E2F TRANSCRIPTION FACTOR AND TUMOR SUPPRESSION$220,470
R01 · FY2002 · CA
PROHIBITION GENE IN GROWTH CONTROL AND TUMOR SUPPRESSION$208,974
R01 · FY2002 · CA
PROHIBITION GENE IN GROWTH CONTROL AND TUMOR SUPPRESSION$202,885
R01 · FY2001 · CA
E2F TRANSCRIPTION FACTOR AND TUMOR SUPPRESSION$125,844
R01 · FY2001 · CA
E2F TRANSCRIPTION FACTOR AND TUMOR SUPPRESSION$107,025
R01 · FY2001 · CA
E2F TRANSCRIPTION FACTOR AND TUMOR SUPPRESSION$247,818
R01 · FY2000 · CA
PROHIBITION GENE IN GROWTH CONTROL AND TUMOR SUPPRESSION$231,619
R01 · FY2000 · CA